In this issue:
Leukaemia selection
Venetoclax and obinutuzumab in CLL with coexisting conditions
Ibrutinib-rituximab or chemoimmunotherapy for CLL
BTK and PLCG2 mutations in real-world CLL after 3 years of ibrutinib
Inotuzumab ozogamicin vs. standard of care in relapsed/ refractory acute ALL
Lymphoma selection
Association of early disease progression and very poor survival in follicular lymphoma
First-line therapy for T-cell lymphomas
Pembrolizumab for classical Hodgkin’s lymphoma after autologous SCT
Intravenous CNS-directed chemotherapy improves survival in testicular DLBCL
Long-term anti-PD-1 efficacy, ±allogenic SCT, in Hodgkin’s lymphoma
Please login below to download this issue (PDF)